Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in:

06.12.2024 | REVIEW

Measurable Residual Disease in Mantle Cell Lymphoma: The Unbearable Lightness of Being Undetectable

verfasst von: Julio Cartagena, Anagha Deshpande, Allison Rosenthal, Mazie Tsang, Talal Hilal, Lisa Rimsza, Razelle Kurzrock, Javier Munoz

Erschienen in: Current Oncology Reports | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

This paper evaluates the benefits and limitations of detecting measurable residual disease (MRD) in mantle cell lymphoma (MCL) and assesses its prognostic value. It also aims to highlight the importance of detecting low MRD levels post-treatment and their application in clinical practice.

Recent findings

Recent studies show that MRD levels predict relapse and survival outcomes in hematologic neoplasms, including MCL. RT-qPCR is currently the most used method due to its high reproducibility and sensitivity. Ideal MRD detection should be highly sensitive, cost-effective, and applicable to a wide demographic of patients.

Summary

This paper concludes that MRD detection has prognostic value in MCL but faces limitations in sensitivity and specificity. Further research is needed to establish the significance of low MRD levels before integrating these methods into clinical practice. Improved MRD detection technologies and understanding their impact on clinical outcomes will guide better patient management in MCL.
Literatur
1.
Wang M, Sun L, Qian J, et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009;23:1320–8.PubMedPubMedCentralCrossRef
2.
Wu X, Lu H, Pang T, et al. Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: a meta-analysis. Leuk Res. 2021;108:106605.PubMedCrossRef
3.
Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684–92.PubMedPubMedCentralCrossRef
4.
Lew TE, Minson A, Dickinson M, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol. 2023;10:e142–54.PubMedCrossRef
5.
Ying ZT, Zheng W, Wang XP, et al. The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma. Chin J Cancer. 2012;31:348–53.PubMedPubMedCentralCrossRef
6.
Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–75.PubMedCrossRef
7.
Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250–60.PubMedCrossRef
8.
Hilal T, Wang Z, Almader-Douglas D, Rosenthal A, Reeder CB, Jain T. Rituximab maintenance therapy for mantle cell lymphoma: a systematic review and meta-analysis. Am J Hematol. 2018;93:1220–6.PubMedCrossRef
9.
Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–10.PubMedCrossRef
10.
Dreyling M, Doorduijn JK, Gine E, et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the european MCL network. Blood. 2022;140:1–3.CrossRef
11.
12.
Cliff ERS, Hilal T, Kesselheim AS. Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma. Nat Rev Clin Oncol. 2024;21:1–2.PubMedCrossRef
13.
Wang M, Rule S, Zinzani P, et al. Acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2020;136:38–9.CrossRef
14.
15.
Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559–63.PubMedCrossRef
16.
Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.PubMedPubMedCentralCrossRef
17.
18.
Deshpande A, Wang Y, Munoz J, Jain P. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. Drugs Today (Barc). 2022;58:283–98.PubMedCrossRef
19.
Wang M, Munoz J, Goy A, et al. Three-year follow-up of kte-x19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the zuma-2 study. J Clin Oncol. 2023;41:555–67.PubMedCrossRef
20.
Jain P, Nastoupil L, Westin J, et al. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol. 2021;192:e38–42.PubMedCrossRef
21.
Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41:3988–97.PubMedPubMedCentralCrossRef
22.
Wu S, Blombery P, Westerman D, Tam CS. Utility of measurable residual disease (MRD) assessment in mantle cell lymphoma. Curr Treat Options Oncol 2023.
23.
Hummel M, Tamaru J, Kalvelage B, Stein H. Mantle cell (previously centrocytic) lymphomas express VH genes with no or very little somatic mutations like the physiologic cells of the follicle mantle. Blood. 1994;84:403–7.PubMedCrossRef
24.
Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22:771–82.PubMedCrossRef
25.
van Dongen JJM, van der Velden VHJ, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125:3996–4009.PubMedPubMedCentralCrossRef
26.
Drandi D, Alcantara M, Benmaad I, et al. Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the european MCL network. Hemasphere. 2020;4:e347.PubMedPubMedCentralCrossRef
27.
Shirai R, Osumi T, Keino D, et al. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma. Int J Hematol. 2023;117:910–8.PubMedPubMedCentralCrossRef
28.
Rimokh R, Berger F, Delsol G, et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood. 1994;83:1871–5.PubMedCrossRef
29.
Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood. 2006;107:2271–8.PubMedCrossRef
30.
Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215–23.PubMedCrossRef
31.
Bottcher S, Ritgen M, Buske S, et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica. 2008;93:551–9.PubMedCrossRef
32.
Cheminant M, Derrieux C, Touzart A, et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica. 2016;101:336–45.PubMedPubMedCentralCrossRef
33.
Bayly E, Nguyen V, Binek A, et al. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma. Cytometry B Clin Cytom. 2020;98:385–98.PubMedCrossRef
34.
Smith M, Jegede O, Parekh S, et al. Minimal residual disease (MRD) Assessment in the ecog1411 randomized phase 2 trial of front-line bendamustine-rituximab (br)-based induction followed by rituximab (r) ± lenalidomide (l) consolidation for mantle cell lymphoma (MCL). Blood. 2019;134:751.CrossRef
35.
Morgane C, Coralie D, Aurore T, et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica. 2016;101:336–45.CrossRef
36.
Ching T, Duncan ME, Newman-Eerkes T, et al. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer. 2020;20:612.PubMedPubMedCentralCrossRef
37.
Ladetto M, Bruggemann M, Monitillo L, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28:1299–307.PubMedCrossRef
38.
Epstein-Peterson ZD, Batlevi CL, Caron P, et al. Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: phase ii, investigator-initiated. Single-Center Study Blood. 2020;136:11–2.
39.
Rezazadeh A, Pruett J, Detzner A, et al. Immunoglobulin high throughput sequencing (Ig-HTS) minimal residual disease (MRD) analysis is an effective surveillance tool in patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2024;24:254–9.PubMedCrossRef
40.
Furqan F, Fenske T, Longo W, Johnson B, Hamadani M, Shah N. MRD Status by clonoseq ® is a poor predictor of long-term outcomes after bispecific lv20.19 CAR t-cell therapy for relapsed. Refractory B-Cell NHL Blood. 2022;140:6407–8.
41.
Ananth S, Su Y-J, Hamilton MP, et al. Post-CAR-T minimal residual disease (MRD) monitoring in mantle cell lymphoma enables early relapse detection. Blood. 2023;142:1673.CrossRef
42.
Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–38.PubMedCrossRef
43.
Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–90.PubMedCrossRef
44.
45.
Kato S, Li B, Adashek JJ, et al. Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting. Oncoimmunology. 2022;11:2052410.PubMedPubMedCentralCrossRef
46.
Adashek JJ, Janku F, Kurzrock R. Signed in blood: circulating tumor DNA in cancer diagnosis treatment and screening. Cancers. 2021;13:3600.PubMed
47.
Goodman AM, Holden KA, Jeong AR, et al. Assessing CAR t-cell therapy response using genome-wide sequencing of cell-free dna in patients with b-cell lymphomas. Transplant Cell Ther. 2022;28(30):e1–7.
48.
Agarwal R, Chan YC, Tam CS, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019;25:119–29.PubMedCrossRef
49.
Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378:1211–23.PubMedCrossRef
50.
Stewart CM, Michaud L, Whiting K, et al. Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring. Clin Cancer Res. 2022;28:45–56.PubMedCrossRef
51.
Lakhotia R, Melani C, Dunleavy K, et al. Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. Blood Adv. 2022;6:2667–80.PubMedPubMedCentralCrossRef
52.
Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20:1479–84.PubMedCrossRef
53.
Yang Y, Wang C, Yang Q, et al. Distinct mechanisms define murine B cell lineage immunoglobulin heavy chain (IgH) repertoires. eLife. 2015;4:e09083.PubMedPubMedCentralCrossRef
54.
55.
56.
Paiva B, Puig N, Cedena MT, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38:784–92.PubMedCrossRef
57.
Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988–99.PubMedPubMedCentralCrossRef
58.
Paiva B, San-Miguel J, Avet-Loiseau H. MRD in multiple myeloma: does CR really matter? Blood. 2022;140:2423–8.PubMedCrossRef
59.
Soumerai JD, Mato AR, Dogan A, et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet Haematology. 2021;8:e879–90.PubMedPubMedCentralCrossRef
60.
Thompson PA, Srivastava J, Peterson C, et al. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019;134:1951–9.PubMedPubMedCentralCrossRef
61.
Molica S, Giannarelli D, Montserrat E. Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19:423–30.PubMedCrossRef
62.
Munir T, Moreno C, Owen C, et al. Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the glow study. J Clin Oncol. 2023;41:3689–99.PubMedPubMedCentralCrossRef
63.
Saygin C, Cannova J, Stock W, Muffly L. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022;107:2783–93.PubMedPubMedCentralCrossRef
64.
Logan AC. Measurable residual disease in acute lymphoblastic leukemia: How low is low enough? Best Pract Res Clin Haematol. 2022;35:101407.PubMedCrossRef
65.
Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580.PubMedPubMedCentralCrossRef
66.
Freedman A. Follicular lymphoma: 2015 update on diagnosis and management. Am J Hematol. 2015;90:1171–8.PubMedCrossRef
67.
Luminari S, Manni M, Galimberti S, et al. Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the foll12 study. J Clin Oncol. 2022;40:729–39.PubMedCrossRef
68.
Chase ML, Armand P. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions. Br J Haematol. 2018;180:177–88.PubMedCrossRef
69.
Pott C, Jurinovic V, Trotman J, et al. Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: a prospective analysis of the phase III GALLIUM study. J Clin Oncol. 2024;42:550–61.PubMedCrossRef
70.
Merryman RW, Redd RA, Taranto E, et al. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023;7:4748–59.PubMedCrossRef
71.
Miles B, Mao D, Vardhanabhuti S, et al. Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL). Journal of Clinical Oncology. 2023;41:7547.CrossRef
72.
Munoz J, Deshpande A, Rimsza L, Nowakowski GS, Kurzrock R. Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL. Cancer Treat Rev. 2024;124:102691.PubMedCrossRef
73.
74.
Furqan F, Fenske TS, Longo WL, Johnson B, Hamadani M, Shah NN. MRD Status By Clonoseq ® is a poor predictor of long-term outcomes after bispecific lv20.19 CAR t-cell therapy for relapsed. Refractory B-Cell NHL Blood. 2022;140:6407–8.
Metadaten
Titel
Measurable Residual Disease in Mantle Cell Lymphoma: The Unbearable Lightness of Being Undetectable
verfasst von
Julio Cartagena
Anagha Deshpande
Allison Rosenthal
Mazie Tsang
Talal Hilal
Lisa Rimsza
Razelle Kurzrock
Javier Munoz
Publikationsdatum
06.12.2024
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 12/2024
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-024-01620-8

Weitere Artikel der Ausgabe 12/2024

Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art Review

  • REVIEW

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis

  • Open Access
  • Review

Existing Health Inequities in the Treatment of Advanced and Metastatic Cancers

  • Open Access
  • Review

Paediatric Acute Lymphoblastic Leukaemia: A Narrative Review of Current Knowledge and Advancements

  • REVIEW

Telemedicine and Virtual Interventions in Cancer Rehabilitation: Practical Application, Complications and Future Potentials

  • Open Access
  • Review

Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review

  • REVIEW

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise